We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Innovative Neurodiagnostic Platform Advances Direct Brain Health Diagnosis at Point of Care

By HospiMedica International staff writers
Posted on 30 Dec 2024
Print article
Image: The Delphi-MD device has been granted FDA breakthrough designation technology status (Photo courtesy of QuantalX Neuroscience)
Image: The Delphi-MD device has been granted FDA breakthrough designation technology status (Photo courtesy of QuantalX Neuroscience)

An innovative point-of-care neurodiagnostic platform designed specifically for nerve stimulation for diagnostic purposes has set a new standard in brain health by enabling objective, personalized treatment options.

QuantalX Neuroscience’s (New York, NY, USA) Delphi-MD (Direct Electrophysiological Imaging Device) platform provides precise, early detection of brain abnormalities related to various conditions, including stroke, dementia (Alzheimer's, Lewy Body Disease, Vascular Dementia), Parkinson's Disease, Normal Pressure Hydrocephalus (NPH), Traumatic Brain Injury (TBI), and general brain health evaluations. By filling significant gaps in neurological care, the Delphi-MD offers clinicians non-invasive, radiation-free insights into brain function, marking a pioneering advancement in healthcare. This innovative method enables precision-focused treatments, ultimately improving patient outcomes and enhancing quality of life.

The Delphi-MD platform marks a significant advancement in neurodiagnostic technology, presenting healthcare professionals with an objective and user-friendly tool to aid in better care decisions. The system has received U.S. Food and Drug Administration (FDA) clearance for its innovative Delphi stimulator. Additionally, Delphi-MD has been granted FDA Breakthrough Designation Device status twice—first for identifying patients at risk for stroke and dementia, and second for detecting NPH and predicting treatment outcomes following ventriculoperitoneal shunt (VPS) surgery.

"We are thrilled to announce this FDA clearance for our Delphi stimulator" said Iftach Dolev PhD, CEO and Co-Founder of QuantalX. "This is a significant step forward in our path to revolutionizing the world of neurodiagnostics, allowing us to make a lasting impact on brain health and elevate standards in patient care as we accelerate our US market penetration. Our team remains committed to pioneering innovations that advance medical science and deliver game-changing solutions for clinicians and patients alike."

Related Links:
QuantalX Neuroscience

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Hemodynamic Monitoring Sensor
FloTrac
New
Bone Marrow Biopsy Needle
BEST-LISAS

Print article

Channels

Surgical Techniques

view channel
Image: The magnetics microrobots removed blood clots from sheep iliac artery (Photo courtesy of University of Twente)

Screw-Shaped Magnetic Microrobots to Transform Treatment for Patients with Inoperable Blood Clots

Cardiovascular conditions such as thrombosis pose a significant global health issue, with blood clots being responsible for one in four deaths worldwide each year. A blood clot can obstruct a blood vessel,... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.